Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for wet age-related macular degeneration
2005-006014-18Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in exudative macular degeneration, sponsored by Policlinico Gemelli. Primary endpoints: Reduction of macular degeneration and Improvement in visual acuity. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2005-006014-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006014-18.